| Year |
Citation |
Score |
| 2020 |
Carbone M, Arron ST, Beutler B, Bononi A, Cavenee W, Cleaver JE, Croce CM, D'Andrea A, Foulkes WD, Gaudino G, Groden JL, Henske EP, Hickson ID, Hwang PM, Kolodner RD, et al. Tumour predisposition and cancer syndromes as models to study gene-environment interactions. Nature Reviews. Cancer. PMID 32472073 DOI: 10.1038/S41568-020-0265-Y |
0.345 |
|
| 2020 |
Rajesh Y, Biswas A, Kumar U, Banerjee I, Das S, Maji S, Das SK, Emdad L, Cavenee WK, Mandal M, Fisher PB. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 32409605 DOI: 10.1073/pnas.1921531117 |
0.315 |
|
| 2020 |
Harachi M, Masui K, Honda H, Muragaki Y, Kawamata T, Cavenee WK, Mischel PS, Shibata N. Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. Molecular Cancer Research : McR. PMID 32366675 DOI: 10.1158/1541-7786.Mcr-20-0024 |
0.32 |
|
| 2020 |
Das SK, Maji S, Wechman SL, Bhoopathi P, Pradhan AK, Talukdar S, Sarkar D, Landry J, Guo C, Wang XY, Cavenee WK, Emdad L, Fisher PB. MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. Pharmacological Research. 104695. PMID 32061839 DOI: 10.1016/J.Phrs.2020.104695 |
0.316 |
|
| 2019 |
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Cavenee WK, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 36: 690-691. PMID 31821785 DOI: 10.1016/J.Ccell.2019.11.008 |
0.517 |
|
| 2019 |
Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, ... ... Cavenee WK, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism. PMID 31303424 DOI: 10.1016/J.Cmet.2019.06.014 |
0.584 |
|
| 2019 |
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Cavenee WK, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 35: 816. PMID 31085179 DOI: 10.1016/j.ccell.2019.04.011 |
0.517 |
|
| 2019 |
Orellana L, Thorne AH, Lema R, Gustavsson J, Parisian AD, Hospital A, Cordeiro TN, Bernadó P, Scott AM, Brun-Heath I, Lindahl E, Cavenee WK, Furnari FB, Orozco M. Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. Proceedings of the National Academy of Sciences of the United States of America. PMID 31028138 DOI: 10.1073/Pnas.1821442116 |
0.589 |
|
| 2019 |
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Cavenee WK, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. PMID 30827889 DOI: 10.1016/J.Ccell.2019.01.020 |
0.548 |
|
| 2019 |
Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, et al. Blockade of a laminin-411 - Notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment crosstalk. Cancer Research. PMID 30659021 DOI: 10.1158/0008-5472.Can-18-2725 |
0.62 |
|
| 2019 |
Masui K, Onizuka H, Cavenee WK, Mischel PS, Shibata N. Metabolic reprogramming in the pathogenesis of glioma: Update. Neuropathology : Official Journal of the Japanese Society of Neuropathology. PMID 30609184 DOI: 10.1111/Neup.12535 |
0.323 |
|
| 2018 |
Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee WK, Das SK, Emdad L, Fisher PB. Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. Autophagy. 1-2. PMID 30118375 DOI: 10.1080/15548627.2018.1502564 |
0.624 |
|
| 2018 |
Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB. Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 9: 16217. PMID 29799523 DOI: 10.1038/Ncomms16217 |
0.456 |
|
| 2018 |
Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee WK, Das SK, Emdad L, Fisher PB. MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 29760085 DOI: 10.1073/Pnas.1721650115 |
0.598 |
|
| 2018 |
Benitez JA, Zanca C, Ma J, Cavenee WK, Furnari FB. Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. Journal of Visualized Experiments : Jove. PMID 29757276 DOI: 10.3791/57448 |
0.571 |
|
| 2018 |
Sun L, Yu S, Xu H, Zheng Y, Lin J, Wu M, Wang J, Wang A, Lan Q, Furnari F, Cavenee W, Purow B, Li M. FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene. PMID 29321665 DOI: 10.1038/S41388-017-0068-0 |
0.691 |
|
| 2017 |
Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, ... ... Cavenee WK, et al. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes & Development. PMID 28724615 DOI: 10.1101/Gad.300079.117 |
0.646 |
|
| 2017 |
Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 8: 15223. PMID 28497778 DOI: 10.1038/ncomms15223 |
0.579 |
|
| 2017 |
Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. PMID 28178237 DOI: 10.1038/Nature21356 |
0.524 |
|
| 2017 |
Koga T, Benitez J, Markmiller S, D’Antonio M, Parisian A, Saberi S, Turner K, Hessenauer M, Thorne AH, Zanca C, Mischel P, Frazer K, Yeo G, Cavenee W, Furnari F. TMOD-42. CRISPR/Cas9-EDITED HUMAN NEURAL STEM CELLS GIVE RISE TO BRAIN TUMORS RESEMBLING GLIOBLASTOMAS Neuro-Oncology. 19: vi263-vi263. DOI: 10.1093/Neuonc/Nox168.1078 |
0.587 |
|
| 2016 |
Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee WK, Wei J, Purves A, De SK, Pellecchia M, et al. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proceedings of the National Academy of Sciences of the United States of America. PMID 28011764 DOI: 10.1073/Pnas.1616100114 |
0.597 |
|
| 2016 |
Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 27825958 DOI: 10.1016/J.Jconrel.2016.11.001 |
0.684 |
|
| 2016 |
Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, ... ... Cavenee WK, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/J.Ccell.2016.09.008 |
0.587 |
|
| 2016 |
Masui K, Shibata N, Cavenee WK, Mischel PS. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 27427440 DOI: 10.1002/Bies.201600026 |
0.376 |
|
| 2016 |
Masui K, Cavenee WK, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathology. PMID 27295313 DOI: 10.1007/S10014-016-0265-5 |
0.303 |
|
| 2016 |
Thorne AH, Orellana L, Parisian A, Cavenee W, Furnari F. CSIG-22. MUTATIONAL HETEROGENEITY OF THE EGFR EXTRACELLULAR DOMAIN PROMOTES AN ONCOGENIC UNTETHERED TRANSITIONAL CONFORMATION AND THE POTENTIAL FOR GREATER THERAPEUTIC TARGETING IN GBM PATIENTS Neuro-Oncology. 18: vi45-vi45. DOI: 10.1093/Neuonc/Now212.183 |
0.603 |
|
| 2015 |
Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, ... ... Cavenee WK, et al. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell. PMID 26455392 DOI: 10.1016/J.Molcel.2015.09.002 |
0.628 |
|
| 2015 |
Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 26170313 DOI: 10.1073/Pnas.1511759112 |
0.382 |
|
| 2015 |
Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, ... ... Cavenee WK, et al. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget. 6: 11751-67. PMID 26059434 DOI: 10.18632/Oncotarget.3996 |
0.621 |
|
| 2015 |
Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, Nykter M, Cavenee WK, Zhang W. IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene. PMID 25893308 DOI: 10.1038/onc.2015.131 |
0.419 |
|
| 2015 |
Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews. Cancer. 15: 302-10. PMID 25855404 DOI: 10.1038/nrc3918 |
0.639 |
|
| 2015 |
Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Research. 75: 394-404. PMID 25432173 DOI: 10.1158/0008-5472.Can-14-2004 |
0.633 |
|
| 2015 |
Costa ET, Barnabé GF, Li M, Dias AA, Machado TR, Asprino PF, Cavalher FP, Ferreira EN, Del Mar Inda M, Nagai MH, Malnic B, Duarte ML, Leite KR, de Barros AC, Carraro DM, ... ... Cavenee W, et al. Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals. Oncogene. 34: 1270-9. PMID 24662834 DOI: 10.1038/Onc.2014.70 |
0.639 |
|
| 2015 |
Chen C, Kozono D, Li J, Nitta M, Sampetrean O, Ng K, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan V, Zhu S, Zhu K, Matsui H, Harismendy O, Hua W, ... ... Cavenee W, et al. Abstract PR02: Dynamic epigenetic regulation of glioblastoma tumorigenicity through a LSD1-MYC-OLIG2 axis Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr02 |
0.609 |
|
| 2015 |
Zanca C, Cavenee W, Furnari F. Abstract B37: Tumor heterogeneity contributes to anti-EGFR therapy resistance in glioblastoma Brain. 75. DOI: 10.1158/1538-7445.Brain15-B37 |
0.722 |
|
| 2015 |
Benitez J, Boyer A, Camargo F, Zanca C, Ma J, Jameson N, Cavenee W, Furnari F. CBIO-04DAXX INHIBITION SUPPRESSES TUMOR GROWTH IN PTEN-DEFICIENT HUMAN GLIOBLASTOMAS Neuro-Oncology. 17: v55.4-v55. DOI: 10.1093/Neuonc/Nov209.04 |
0.661 |
|
| 2015 |
Thorne AH, Orellana L, Parisian A, Cavenee W, Furnari F. ATPS-86MUTATIONS IN THE EGF RECEPTOR EXTRACELLULAR DOMAIN REVEAL AN UNTETHERED TRANSITIONAL STATE WHICH MEDIATES mAb806 BINDING Neuro-Oncology. 17: v37.3-v37. DOI: 10.1093/Neuonc/Nov204.86 |
0.657 |
|
| 2014 |
Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. PMID 25347738 DOI: 10.1038/onc.2014.336 |
0.654 |
|
| 2014 |
Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... Cavenee WK, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/Jci73093 |
0.627 |
|
| 2014 |
Kawashima N, Qu H, Lobaton M, Zhu Z, Sollogoub M, Cavenee WK, Handa K, Hakomori SI, Zhang Y. Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. Oncology Letters. 7: 933-940. PMID 24944646 DOI: 10.3892/Ol.2014.1887 |
0.346 |
|
| 2014 |
Masui K, Cavenee WK, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism: Tem. 25: 364-73. PMID 24856037 DOI: 10.1016/J.Tem.2014.04.002 |
0.312 |
|
| 2014 |
Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, Cavenee W, Elledge S, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 5: 882-93. PMID 24658464 DOI: 10.18632/Oncotarget.1801 |
0.639 |
|
| 2014 |
Masui K, Cavenee WK, Mischel PS. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle (Georgetown, Tex.). 13: 1053-4. PMID 24583874 DOI: 10.4161/Cc.28377 |
0.358 |
|
| 2014 |
Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee WK. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Research. 74: 1429-39. PMID 24436148 DOI: 10.1158/0008-5472.Can-13-2117 |
0.615 |
|
| 2014 |
Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... Cavenee WK, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/Science.1241328 |
0.643 |
|
| 2014 |
Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK, Cheng SY. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 33: 2504-12. PMID 23728337 DOI: 10.1038/onc.2013.198 |
0.668 |
|
| 2014 |
Zanca C, Inda MdM, Bonavia R, Wykosky J, Verkhusha V, Cavenee W, Furnari F. Abstract 4933: In vivo visualization of heterogeneous cancer cell populations by fluorescence molecular tomography Cancer Research. 74: 4933-4933. DOI: 10.1158/1538-7445.Am2014-4933 |
0.706 |
|
| 2014 |
Muir S, Nathanson J, Wilbert M, Yeo G, Furnari F, Arden K, Cavenee W. Abstract 3558: The role of miRNA in PAX3-FKHR positive rhabdomyosarcoma Cancer Research. 74: 3558-3558. DOI: 10.1158/1538-7445.Am2014-3558 |
0.57 |
|
| 2014 |
Chen C, Shen Y, Nitta M, Futalan D, Taich Z, Treiber J, Stevens D, Chen H, Carter B, Esashi F, Sarkaria J, Furnari F, Cavenee W, Desai A. DN-01 * BYPASSING GLIOBLASTOMA RESISTANCE TO EGFR INHIBITORS BY SYNTHETIC LETHALITY Neuro-Oncology. 16: v62-v62. DOI: 10.1093/Neuonc/Nou245.1 |
0.657 |
|
| 2014 |
Chen C, Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha D, Vandenberg S, Ramakrishnan V, Zhu S, Furnari F, Matsui H, Harismendy O, Cavenee W, Mao Y, et al. CB-04 * EPIGENETIC REGULATION OF GLIOBLASTOMA TUMORIGENICITY: A HYBRID MODEL Neuro-Oncology. 16: v41-v41. DOI: 10.1093/Neuonc/Nou241.4 |
0.631 |
|
| 2014 |
Furnari F, Gomez G, Volinia S, Croce C, Zanca C, Li M, Gutmann D, Brennan C, Cavenee W. MUTANT EGFR SUPPRESSION OF MICRORNA-9 INDUCES FOXP1 TO ENHANCE GLIOBLASTOMA TUMORIGENICITY Neuro-Oncology. 16: iii14-iii15. DOI: 10.1093/Neuonc/Nou206.52 |
0.588 |
|
| 2013 |
Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biology & Medicine. 10: 192-205. PMID 24349829 DOI: 10.7497/j.issn.2095-3941.2013.04.003 |
0.673 |
|
| 2013 |
Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... Cavenee WK, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.Ccr-13-0527 |
0.632 |
|
| 2013 |
Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, ... ... Cavenee WK, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/J.Cmet.2013.04.013 |
0.378 |
|
| 2013 |
Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, ... ... Cavenee WK, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.Cd-12-0502 |
0.459 |
|
| 2013 |
Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. Plos Genetics. 9: e1003253. PMID 23459592 DOI: 10.1371/Journal.Pgen.1003253 |
0.637 |
|
| 2013 |
Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/Carcin/Bgt086 |
0.499 |
|
| 2013 |
Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/Pnas.1217602110 |
0.653 |
|
| 2013 |
Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee WK, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. International Journal of Cancer. Journal International Du Cancer. 132: 509-20. PMID 22729867 DOI: 10.1002/Ijc.27690 |
0.668 |
|
| 2013 |
Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Cavenee W, ... ... Cavenee W, ... ... Cavenee W, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174 |
0.565 |
|
| 2012 |
Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, ... ... Cavenee WK, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America. 109: 14164-9. PMID 22891331 DOI: 10.1073/Pnas.1211962109 |
0.659 |
|
| 2012 |
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & Development. 26: 756-84. PMID 22508724 DOI: 10.1101/Gad.187922.112 |
0.526 |
|
| 2012 |
Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee WK, et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 109: 3018-23. PMID 22323579 DOI: 10.1073/Pnas.1121457109 |
0.668 |
|
| 2012 |
Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Current Cancer Drug Targets. 12: 197-209. PMID 22268382 |
0.621 |
|
| 2012 |
Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, Furnari FB. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene. 31: 4054-66. PMID 22139077 DOI: 10.1038/onc.2011.563 |
0.647 |
|
| 2012 |
Wykosky J, Cavenee W, Furnari F. Abstract A27: PI3K/Akt pathway-dependent and -independent mechanisms of resistance to EGFR tyrosine kinase inhibitors in glioblastoma Clinical Cancer Research. 18: A27-A27. DOI: 10.1158/1078-0432.Mechres-A27 |
0.662 |
|
| 2012 |
Kijima N, Hosen N, Kagawa N, Hashimoto N, Chiba Y, Kinoshita M, Sugiyama H, Yoshimine T, Kim YZ, Kim KH, Lee EH, Hu B, Sim H, Mohan N, Agudelo-Garcia P, ... ... Cavenee W, ... ... Cavenee WK, ... ... Cavenee WK, et al. LAB-CELL BIOLOGY AND SIGNALING Neuro-Oncology. 14: vi7-vi20. DOI: 10.1093/Neuonc/Nos220 |
0.565 |
|
| 2012 |
Proescholdt MA, Merrill MJ, Stoerr E, Lohmeier A, Brawanski A, Sim H, Hu B, Pineda CA, Yoon S, Viapiano MS, Rajappa P, Cobb WS, Huang Y, Lyden DC, Bromberg J, ... ... Cavenee W, et al. LAB-ANGIOGENESIS AND INVASION Neuro-Oncology. 14: vi1-vi6. DOI: 10.1093/Neuonc/Nos219 |
0.577 |
|
| 2012 |
Furnari F, Fenton T, Zhou H, Marie S, Mischel P, Cavenee W. 66 Proffered Paper: PTEN Phosphorylation by Fibroblast Growth Factor Receptors and SRC Mediates Resistance to Epidermal Growth Factor Receptor Inhibitors in Glioblastoma European Journal of Cancer. 48: S16. DOI: 10.1016/S0959-8049(12)70770-0 |
0.57 |
|
| 2011 |
Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. The Journal of Experimental Medicine. 208: 2657-73. PMID 22162832 DOI: 10.1084/Jem.20111102 |
0.694 |
|
| 2011 |
Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, ... ... Cavenee WK, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.Cd-11-0124 |
0.39 |
|
| 2011 |
Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, Sarkaria JN, Nagane M, ... ... Cavenee WK, et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. The Journal of Clinical Investigation. 121: 4670-84. PMID 22080864 DOI: 10.1172/Jci58559 |
0.64 |
|
| 2011 |
Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 15984-9. PMID 21896743 DOI: 10.1073/Pnas.1113416108 |
0.676 |
|
| 2011 |
Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science. 124: 2938-50. PMID 21878501 DOI: 10.1242/jcs.083295 |
0.595 |
|
| 2011 |
Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Molecular Cancer Research : McR. 9: 1100-11. PMID 21693595 DOI: 10.1158/1541-7786.Mcr-11-0007 |
0.506 |
|
| 2011 |
Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Research. 71: 4055-60. PMID 21628493 DOI: 10.1158/0008-5472.CAN-11-0153 |
0.59 |
|
| 2011 |
Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee WK, Furnari FB, Bogler O. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR. Journal of Proteome Research. 10: 1343-52. PMID 21214269 DOI: 10.1021/Pr101075E |
0.653 |
|
| 2011 |
Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer. 30: 5-12. PMID 21192840 DOI: 10.5732/Cjc.010.10542 |
0.66 |
|
| 2011 |
Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, ... ... Cavenee WK, et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. The Journal of Clinical Investigation. 121: 161-73. PMID 21183793 DOI: 10.1172/Jci44798 |
0.562 |
|
| 2011 |
Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, D'Andrea A, Chen CC. Correction: Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy Plos One. 6. DOI: 10.1371/Annotation/9B9Cc4Ae-Ad56-464F-Ab97-59F096B5C0Eb |
0.485 |
|
| 2011 |
Li M, Cavenee W, Furnari F. Abstract 1193: Guanylate binding protein-1, a novel oncogenic gene in glioblastoma Cancer Research. 71: 1193-1193. DOI: 10.1158/1538-7445.Am2011-1193 |
0.691 |
|
| 2011 |
Inda MDM, Bonavia R, Vandenberg S, Cavenee W, Furnari F. Abstract 1129: Function of mutant EGFR in maintaining glioblastoma growth and heterogeneity Cancer Research. 71: 1129-1129. DOI: 10.1158/1538-7445.Am2011-1129 |
0.696 |
|
| 2011 |
Wykosky JE, Cavenee W, Furnari F. Abstract B73: Molecular mechanisms of glioma resistance to EGFR tyrosine kinase inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B73 |
0.671 |
|
| 2010 |
Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes & Development. 24: 1731-45. PMID 20713517 DOI: 10.1101/Gad.1890510 |
0.653 |
|
| 2010 |
Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee WK, Robertson GP. KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. Journal of the National Cancer Institute. 102: 1131-47. PMID 20660366 DOI: 10.1093/Jnci/Djq218 |
0.368 |
|
| 2010 |
Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. Plos One. 5: e10767. PMID 20532243 DOI: 10.1371/Journal.Pone.0010767 |
0.614 |
|
| 2010 |
Huang PH, Miraldi ER, Xu AM, Kundukulam VA, Del Rosario AM, Flynn RA, Cavenee WK, Furnari FB, White FM. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Molecular Biosystems. 6: 1227-37. PMID 20461251 DOI: 10.1039/C001196G |
0.605 |
|
| 2010 |
Wykosky J, Mukasa A, Furnari F, Cavenee WK. Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell Cycle (Georgetown, Tex.). 9: 1661-2. PMID 20404502 DOI: 10.4161/Cc.9.9.11592 |
0.54 |
|
| 2010 |
Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America. 107: 2616-21. PMID 20133782 DOI: 10.1073/Pnas.0914356107 |
0.67 |
|
| 2010 |
Latha K, Chumbalkar V, Li M, Hwang Y, Gururaj A, Maywald R, Dakeng S, Dao L, Baggerly K, Sawaya R, Cavenee W, Furnaru F, Bögler O. Abstract 3125: EGFRvIII translocates to the nucleus and regulates gene transcription with STAT5 Cancer Research. 70: 3125-3125. DOI: 10.1158/1538-7445.Am10-3125 |
0.529 |
|
| 2010 |
Li M, Furnari F, Cavenee W. Abstract 265: EGFR positively regulates GBP1 expression to promote glioma cell invasion Cancer Research. 70: 265-265. DOI: 10.1158/1538-7445.Am10-265 |
0.697 |
|
| 2010 |
Wykosky J, Mukasa A, Chin L, Cavenee W, Furnari F. Abstract PR6: Resistance to EGFR inhibition via the emergence of EGFRvIII-independent tumor growth-promoting mechanisms in glioblastoma Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr6 |
0.71 |
|
| 2009 |
Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Cavenee WK, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.Can-09-0347 |
0.684 |
|
| 2009 |
Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee WK, Bachoo RM, Burma S. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Research. 69: 4252-9. PMID 19435898 DOI: 10.1158/0008-5472.Can-08-4853 |
0.616 |
|
| 2009 |
Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee WK, Old LJ, Stockert E, Ritter G, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of the United States of America. 106: 5082-7. PMID 19289842 DOI: 10.1073/Pnas.0811559106 |
0.333 |
|
| 2009 |
Read RD, Cavenee WK, Furnari FB, Thomas JB. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. Plos Genetics. 5: e1000374. PMID 19214224 DOI: 10.1371/journal.pgen.1000374 |
0.66 |
|
| 2009 |
Bonavia R, Inda M, Johns T, Cavenee W, Furnari F. Abstract A181: Dissecting the crosstalk between wt and mutant EGFR in glioblastoma multiforme Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A181 |
0.706 |
|
| 2008 |
Roeb W, Boyer A, Cavenee WK, Arden KC. Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle (Georgetown, Tex.). 7: 837-41. PMID 18414034 |
0.307 |
|
| 2008 |
Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee WK, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 13: 355-64. PMID 18394558 DOI: 10.1016/J.Ccr.2008.02.010 |
0.524 |
|
| 2008 |
Amos S, Redpath GT, Carpenter JE, diPierro CG, Parsons SJ, Huang S, Habib A, Cavenee W, Hussaini IM. EGFR- and EGFR VIII–Mediated Regulation of Urokinase Promotes Astrocytic Tumor Invasion Via the C-SRC/MEK/AP-1 Signaling Pathways Neuro-Oncology. 10: 761. DOI: 10.1215/15228517-2008-051 |
0.46 |
|
| 2007 |
Huang PH, Cavenee WK, Furnari FB, White FM. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle (Georgetown, Tex.). 6: 2750-4. PMID 17986864 DOI: 10.4161/Cc.6.22.4922 |
0.634 |
|
| 2007 |
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & Development. 21: 2683-710. PMID 17974913 DOI: 10.1101/Gad.1596707 |
0.566 |
|
| 2007 |
Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 104: 12867-72. PMID 17646646 DOI: 10.1073/Pnas.0705158104 |
0.63 |
|
| 2007 |
Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1911-25. PMID 17363548 DOI: 10.1158/1078-0432.Ccr-06-1453 |
0.62 |
|
| 2007 |
Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, et al. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. The Journal of Clinical Investigation. 117: 346-52. PMID 17256054 DOI: 10.1172/Jci30446 |
0.358 |
|
| 2007 |
White F, Huang P, Cavenee W, Furnari F. 121 INVITED Network analysis of cellular signalling European Journal of Cancer Supplements. 5: 33-34. DOI: 10.1016/s1359-6349(07)70235-5 |
0.465 |
|
| 2006 |
Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.Can-04-4392 |
0.456 |
|
| 2006 |
Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. The Journal of Biological Chemistry. 281: 26562-8. PMID 16829519 DOI: 10.1074/Jbc.M605391200 |
0.62 |
|
| 2006 |
Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Divicio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, et al. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell. 9: 379-90. PMID 16697958 DOI: 10.1016/J.Ccr.2006.03.028 |
0.55 |
|
| 2006 |
Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, DePinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans (DOI:10.1016/j.ccr.2006.03.028) Cancer Cell. 10: 171. DOI: 10.1016/J.Ccr.2006.07.012 |
0.549 |
|
| 2005 |
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918 |
0.398 |
|
| 2005 |
Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6390-9. PMID 16144944 DOI: 10.1158/1078-0432.Ccr-04-2653 |
0.619 |
|
| 2005 |
Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee WK. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle (Georgetown, Tex.). 4: 540-2. PMID 15753657 DOI: 10.4161/Cc.4.4.1614 |
0.587 |
|
| 2005 |
Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America. 102: 2703-6. PMID 15659546 DOI: 10.1073/Pnas.0409370102 |
0.548 |
|
| 2005 |
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. 4: 101-12. PMID 15657358 |
0.408 |
|
| 2004 |
Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathology. 21: 53-6. PMID 15700833 DOI: 10.1007/Bf02484510 |
0.647 |
|
| 2004 |
Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I, Bögler O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Molecular and Cellular Biology. 24: 8981-93. PMID 15456872 DOI: 10.1128/Mcb.24.20.8981-8993.2004 |
0.586 |
|
| 2003 |
Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CV, Kelso J, Nagai MA, Ojopi EP, ... ... Cavenee W, et al. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proceedings of the National Academy of Sciences of the United States of America. 100: 13418-23. PMID 14593198 DOI: 10.1073/Pnas.1233632100 |
0.53 |
|
| 2003 |
Schmidt MH, Furnari FB, Cavenee WK, Bögler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proceedings of the National Academy of Sciences of the United States of America. 100: 6505-10. PMID 12734385 DOI: 10.1073/Pnas.1031790100 |
0.612 |
|
| 2003 |
Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proceedings of the National Academy of Sciences of the United States of America. 100: 639-44. PMID 12515857 DOI: 10.1073/Pnas.232686499 |
0.406 |
|
| 2002 |
Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Research. 62: 6764-9. PMID 12438278 |
0.653 |
|
| 2002 |
De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee WK. A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. Journal of Neurochemistry. 81: 575-88. PMID 12065666 DOI: 10.1046/J.1471-4159.2002.00847.X |
0.523 |
|
| 2002 |
Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. International Journal of Cancer. Journal International Du Cancer. 98: 398-408. PMID 11920591 DOI: 10.1002/Ijc.10189 |
0.396 |
|
| 2002 |
Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathology (Zurich, Switzerland). 12: 12-20. PMID 11770895 |
0.328 |
|
| 2001 |
Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. Journal of Neurosurgery. 95: 472-9. PMID 11565870 DOI: 10.3171/Jns.2001.95.3.0472 |
0.425 |
|
| 2001 |
Klingler-Hoffmann M, Fodero-Tavoletti MT, Mishima K, Narita Y, Cavenee WK, Furnari FB, Huang HJ, Tiganis T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. The Journal of Biological Chemistry. 276: 46313-8. PMID 11514572 DOI: 10.1074/jbc.M106571200 |
0.666 |
|
| 2001 |
Chuenkova MV, Furnari FB, Cavenee WK, Pereira MA. Trypanosoma cruzi trans-sialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling. Proceedings of the National Academy of Sciences of the United States of America. 98: 9936-41. PMID 11481434 DOI: 10.1073/pnas.161298398 |
0.583 |
|
| 2001 |
Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Research. 61: 5355-61. PMID 11454674 |
0.405 |
|
| 2001 |
Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Research. 61: 5349-54. PMID 11454673 |
0.351 |
|
| 2001 |
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes & Development. 15: 1311-33. PMID 11390353 DOI: 10.1101/Gad.891601 |
0.563 |
|
| 2001 |
Fan X, Furnari FB, Cavenee WK, Castresana JS. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. International Journal of Oncology. 18: 1023-6. PMID 11295051 |
0.544 |
|
| 2001 |
Nagane M, Lin H, Cavenee WK, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Letters. 162: S17-S21. PMID 11164186 DOI: 10.1016/S0304-3835(00)00648-0 |
0.422 |
|
| 2000 |
Bögler O, Furnari FB, Kindler-Roehrborn A, Sykes VW, Yung R, Huang HJ, Cavenee WK. SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro-Oncology. 2: 6-15. PMID 11302255 DOI: 10.1093/Neuonc/2.1.6 |
0.546 |
|
| 2000 |
Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X, Baserga R. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene. 19: 2687-94. PMID 10851068 DOI: 10.1038/sj.onc.1203587 |
0.583 |
|
| 1999 |
Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene. 18: 5239-45. PMID 10498874 DOI: 10.1038/Sj.Onc.1202910 |
0.351 |
|
| 1999 |
Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene. 18: 3936-43. PMID 10435616 DOI: 10.1038/sj.onc.1202774 |
0.62 |
|
| 1999 |
Bögler O, Nagane M, Gillis J, Huang HJ, Cavenee WK. Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 10: 73-86. PMID 10074901 |
0.329 |
|
| 1998 |
Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Research. 58: 5002-8. PMID 9823298 |
0.614 |
|
| 1998 |
Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 95: 9418-23. PMID 9689095 DOI: 10.1073/Pnas.95.16.9418 |
0.586 |
|
| 1998 |
Carethers JM, Furnari FB, Zigman AF, Lavine JE, Jones MC, Graham GE, Teebi AS, Huang HJ, Ha HT, Chauhan DP, Chang CL, Cavenee WK, Boland CR. Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome. Cancer Research. 58: 2724-6. PMID 9661881 |
0.529 |
|
| 1998 |
Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proceedings of the National Academy of Sciences of the United States of America. 95: 5724-9. PMID 9576951 DOI: 10.1073/pnas.95.10.5724 |
0.395 |
|
| 1998 |
Carethers J, Funari F, Zigman A, Lavine J, Jones M, Graham G, Teebi A, Huang H, Chauhan D, Chang C, Cavenee W, Boland C. Lack of mutations of the PTEN tumor suppressor gene in three Bannaya-Riley-Ruvalcaba syndrome patients Gastroenterology. 114: A574. DOI: 10.1016/S0016-5085(98)82335-4 |
0.372 |
|
| 1997 |
Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene. 15: 2013-20. PMID 9366518 DOI: 10.1038/Sj.Onc.1201389 |
0.336 |
|
| 1997 |
Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proceedings of the National Academy of Sciences of the United States of America. 94: 12479-84. PMID 9356475 DOI: 10.1073/pnas.94.23.12479 |
0.624 |
|
| 1997 |
Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee WK. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Research. 57: 1250-4. PMID 9102208 |
0.325 |
|
| 1997 |
Arap W, Knudsen ES, Wang JY, Cavenee WK, Huang HJ. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. Oncogene. 14: 603-9. PMID 9053859 DOI: 10.1038/Sj.Onc.1200870 |
0.333 |
|
| 1997 |
Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. The Journal of Biological Chemistry. 272: 2927-35. PMID 9006938 DOI: 10.1074/jbc.272.5.2927 |
0.386 |
|
| 1996 |
Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJS. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis Cancer Research. 56: 5079-5086. PMID 8895767 |
0.429 |
|
| 1996 |
Furnari FB, Huang HJ, Cavenee WK. Molecular biology of malignant degeneration of astrocytoma. Pediatric Neurosurgery. 24: 41-9. PMID 8817614 |
0.569 |
|
| 1996 |
Wasserman LM, Newsham I, Huang HJS, Cavenee WK. cAMP effects on myogenic gene expression in rhabdomyosarcoma cells Experimental Cell Research. 227: 55-62. PMID 8806451 DOI: 10.1006/Excr.1996.0249 |
0.311 |
|
| 1996 |
Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJS. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors Cancer Research. 56: 3859-3861. PMID 8752145 |
0.381 |
|
| 1995 |
Furnari FB, Huang HJ, Cavenee WK. Genetics and malignant progression of human brain tumours. Cancer Surveys. 25: 233-75. PMID 8718522 |
0.545 |
|
| 1995 |
Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Research. 55: 1351-4. PMID 7882335 |
0.593 |
|
| 1995 |
Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Su Huang HJ. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Research. 55: 1941-5. PMID 7728764 |
0.621 |
|
| 1995 |
Besnard-Guerin C, Cavenee W, Newsham I. The t(11;22)(p15.5;q11.23) in a retroperitoneal rhabdoid tumor also includes a regional deletion distal to CRYBB2 on 22q Genes Chromosomes and Cancer. 13: 145-150. PMID 7669732 DOI: 10.1002/Gcc.2870130302 |
0.345 |
|
| 1995 |
Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification - Rearrangement in human glioblastomas International Journal of Cancer. 62: 145-148. PMID 7622287 DOI: 10.1002/ijc.2910620206 |
0.371 |
|
| 1995 |
Newsham I, Kindler-Rohrborn A, Daub D, Cavenee W. A constitutional BWS-related t(11;16) chromosome translocation occurring in the same region of chromosome 16 implicated in Wilms' tumors Genes Chromosomes and Cancer. 12: 1-7. PMID 7534105 DOI: 10.1002/Gcc.2870120102 |
0.304 |
|
| 1994 |
Newsham I, Daub D, Besnard-Guerin C, Cavenee W. Molecular sublocalization and characterization of the 11;22 translocation breakpoint in a malignant rhabdoid tumor. Genomics. 19: 433-40. PMID 8188285 DOI: 10.1006/Geno.1994.1091 |
0.371 |
|
| 1994 |
Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJS. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proceedings of the National Academy of Sciences of the United States of America. 91: 7727-7731. PMID 8052651 DOI: 10.1073/pnas.91.16.7727 |
0.44 |
|
| 1994 |
Gessler M, König A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F, Cavenee W, Bruns G. Infrequent mutation of the WT1 gene in 77 Wilms' tumors Human Mutation. 3: 212-222. PMID 8019557 DOI: 10.1002/Humu.1380030307 |
0.405 |
|
| 1994 |
De Plaen E, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Chomez P, De Backer O, Boon T, Arden K, Cavenee W, Brasseur R. Structure, chromosomal localization, and expression of 12 genes of the MAGE family Immunogenetics. 40: 360-369. PMID 7927540 DOI: 10.1007/Bf01246677 |
0.332 |
|
| 1993 |
Newsham I, Cavenee W. Tumors and developmental anomalies associated with Wilms tumor. Medical and Pediatric Oncology. 21: 199-204. PMID 8383280 DOI: 10.1002/Mpo.2950210309 |
0.356 |
|
| 1993 |
Gessler M, König A, Moore J, Qualman S, Arden K, Cavenee W, Bruns G. Homozygous inactivation of WT1 in a Wilms' tumor associated with the WAGR syndrome. Genes, Chromosomes & Cancer. 7: 131-6. PMID 7687865 DOI: 10.1002/Gcc.2870070304 |
0.402 |
|
| 1991 |
Cavenee WK, Scrable HJ, David James C. Molecular genetics of human cancer predisposition and progression Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 247: 199-202. PMID 2011137 DOI: 10.1016/0027-5107(91)90015-G |
0.333 |
|
| 1991 |
Newsham I, Claussen U, Lüdecke HJ, Mason M, Senger G, Horsthemke B, Cavenee W. Microdissection of chromosome band 11p15.5: characterization of probes mapping distal to the HBBC locus. Genes, Chromosomes & Cancer. 3: 108-16. PMID 1676905 DOI: 10.1002/Gcc.2870030205 |
0.323 |
|
| 1989 |
Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, Sapienza C. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting Proceedings of the National Academy of Sciences of the United States of America. 86: 7480-7484. PMID 2798419 DOI: 10.1073/Pnas.86.19.7480 |
0.348 |
|
| 1989 |
Scrable H, Witte D, Shimada H, Seemayer T, Wang-Wuu S, So ukup S, Koufos A, Houghton P, Lampkin B, Cavenee W. Molecular differential pathology of rhabdomyosarcoma Genes Chromosomes and Cancer. 1: 23-35. PMID 2487144 DOI: 10.1002/Gcc.2870010106 |
0.393 |
|
| 1988 |
Hansen MF, Cavenee WK. Tumor suppressors: recessive mutations that lead to cancer. Cell. 53: 173-4. PMID 3282673 DOI: 10.1016/0092-8674(88)90376-5 |
0.333 |
|
| 1984 |
Dryja TP, Cavenee W, White R, Rapaport JM, Petersen R, Albert DM, Bruns GA. Homozygosity of chromosome 13 in retinoblastoma. The New England Journal of Medicine. 310: 550-3. PMID 6694706 DOI: 10.1056/Nejm198403013100902 |
0.364 |
|
| Show low-probability matches. |